
PARP Inhibitors and Ovarian Cancer
Over the past decade, a new class of drugs called PARP inhibitors have been approved by the Food and Drug Administration (FDA) for use in ovarian cancer. Three FDA-approved PARP inhibitors — as well as others that are still under investigation — have offered hope for patients and clinicians in their quest to cure ovarian … Continued